Novel Therapies for Bleeding Disorders

health, fitness, science, life · EN

Innovation is accelerating—not only in communications, computer technology, and artificial intelligence, but also in medical science. For people living with inherited bleeding disorders, this acceleration is transforming what is possible. Over the past decade, treatment advances have reshaped care. Extended half-life factor VIII and IX concentrates have reduced infusion frequency. Factor VIII mimetics such as emicizumab have introduced entirely new mechanisms of action. The first gene therapies for hemophilia A and B are now a reality. Rebalancing agents have entered the therapeutic landscape. And this is only the beginning. A growing pipeline of innovative therapies—subcutaneous treatments, non-factor therapies, gene editing approaches, rebalancing strategies, and more—are in various stages of development. These advances extend beyond hemophilia to include von Willebrand disease and rare bleeding disorders such as Glanzmann Thrombasthenia and others that historically re